[CAS NO. 649748-23-2] PPACK II diTFA
PRODUCTS SPECIFICATIONS [649748-23-2]
DESCRIPTION [649748-23-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 729.07 |
| Molecular Formula | C29H35ClF6N6O7 |
| SMILES | O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.N=C(N)NCCC[C@@H](C(CCl)=O)NC([C@@H](NC([C@H](N)CC1=CC=CC=C1)=O)CC2=CC=CC=C2)=O |
Summary
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor [1] .
In Vitro
PPACK II (0.62-50 μg/mL) diTFA significantly inhibits B-type natriuretic peptide (BNP) proteolysis [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 250 mg/mL ( 342.90 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.3716 mL | 6.8581 mL | 13.7161 mL |
| 5 mM | 0.2743 mL | 1.3716 mL | 2.7432 mL |
| 10 mM | 0.1372 mL | 0.6858 mL | 1.3716 mL |
References
- [1] Kentaro Takayama, et al. Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U. Biopolymers. 2016 Nov 4;106(4):440-5.
- [2] Alexander Belenky, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004 Feb;340(1-2):163-72.
